Method of implanting stimulation lead with biased curved section through the interatrial septum

Information

  • Patent Grant
  • 8781604
  • Patent Number
    8,781,604
  • Date Filed
    Wednesday, April 1, 2009
    15 years ago
  • Date Issued
    Tuesday, July 15, 2014
    10 years ago
Abstract
A lead includes a lead body and an electrode disposed proximate a distal end of the lead body. A retaining member is disposed proximate the distal end of the lead and adapted to retain the electrode proximate an interatrial septum when the retaining member is located on a left atrial side of the interatrial septum.
Description
FIELD OF THE INVENTION

This invention relates to the field of medical leads, and more specifically to an implantable lead.


BACKGROUND

Leads implanted in or about the heart have been used to reverse certain life threatening arrhythmia, or to stimulate contraction of the heart. Electrical energy is applied to the heart via electrodes on the leads to return the heart to normal rhythm.


For example, atrial pacing is accomplished by locating an electrode in the right atrium. However, right atrium pacing and sensing can produce deleterious left heart timing intervals. One technique to apply an energy pulse to the left atrium of the heart is to implant the electrode through the coronary sinus to reach a location below the left atrium. However, it can be difficult to locate the coronary sinus ostium, thus implantation time can be excessive, or the procedure can be unsuccessful. Also, if it desired to apply electrical pulses to both the left atrium and right atrium, two leads may be needed.


SUMMARY

A lead includes a lead body and an electrode disposed proximate a distal end of the lead body. A retaining member is disposed proximate the distal end of the lead and adapted to retain the electrode proximate an interatrial septum when the retaining member is located on a left atrial side of the interatrial septum.


A lead includes a lead body having a shocking electrode disposed proximate a distal end of the lead body. A retaining member is disposed on the lead body and located distally from the shocking electrode. The lead body includes a pre-biased curved section between the shocking electrode and the retaining member.


A method includes inserting a distal tip of a lead through an interatrial septum, deploying a retaining member on the lead on a left atrium side of the interatrial septum such that an electrode on the lead contacts the interatrial septum, and delivering energy pulses to the interatrial septum via the electrode.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a view of a lead, according to at least one embodiment, implanted within a heart.



FIG. 2 shows a distal portion of the lead of FIG. 1.



FIG. 3 shows a distal portion of a lead according to at least one embodiment.



FIG. 4 shows a distal portion of a lead according to at least one embodiment.



FIG. 5 shows a distal portion of a lead according to at least one embodiment.



FIG. 6 shows a view of a distal portion of a lead, according to at least one embodiment.



FIG. 7 shows a view of a lead, according to at least one embodiment, implanted within a heart.



FIG. 8 shows a distal portion of the lead of FIG. 7.



FIG. 9 shows a side view of the lead of FIG. 7.





DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that structural changes may be made without departing from the scope of the present invention. Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.



FIG. 1 shows a view of a lead 100 implanted within a heart 10. Heart 10 generally includes a superior vena cava 12, a right atrium 14, a right ventricle 16, a left ventricle 26, a left atrium 28, and an interatrial septum 30. In one embodiment, lead 100 is adapted to deliver pacing or defibrillation pulses to heart 10 via an electrode 122. Lead 100 is part of an implantable system including a pulse generator 110, such as a pacemaker or defibrillator.


Pulse generator 110 can be implanted in a surgically-formed pocket in a patient's chest or other desired location. Pulse generator 110 generally includes electronic components to perform signal analysis and processing, and control. Pulse generator 110 can include a power supply such as a battery, a capacitor, and other components housed in a case. The device can include microprocessors to provide processing, evaluation, and to determine and deliver electrical shocks and pulses of different energy levels and timing for defibrillation, cardioversion, and pacing to heart 10 in response to cardiac arrhythmia including fibrillation, tachycardia, and bradycardia.


In one embodiment, lead 100 includes a lead body 105 extending from a proximal end 107 to a distal portion 109 and having an intermediate portion 111. Lead 100 includes one or more conductors, such as coiled conductors, to conduct energy from pulse generator 110 to heart 10, and also to receive signals from the heart. The lead further includes outer insulation 112 to insulate the conductor. The conductors are coupled to one or more electrodes, such as electrode 122. Lead terminal pins are attached to pulse generator 110. The system can include a tnipolar system with the case acting as an electrode or a bipolar system.


In one embodiment, lead 100 includes a retaining member 150 disposed on the distal portion 109 of the lead body. As will be further explained below, retaining member 150 is adapted to retain electrode 122 at or near the interatrial septum 30 when the distal end of the lead is mounted to the interatrial septum 30. Since the interatrial septum is so thin (about 3 mm to 5 mm), retaining member 150 provides a technique to hold the lead in position without actively fixating the lead to the thin septum, using a helix, for example. Thus, the lead is easier to implant and the fixation is not as traumatic.


In one embodiment, electrode 122 includes a pacing electrode, such as a ring electrode, adapted for delivering pacing pulses to the left atrium and/or the right atrium of the heart at the interatrial septum 30. For instance, lead 100 can be designed for placement of pacing electrode 122 near or within the interatrial septum 30 to deliver energy pulses which simultaneously affect the left and right atriums. This allows directly pacing and sensing at the left atrium. By locating the electrode at the interatrial septum, the present system can eliminate uncertainties regarding interatrial conduction time. Moreover, by providing simultaneous depolarization of both the left atrium and right atrium it results in decreased incidence of re-entrant AT. In some examples, electrode 122 can be a defibrillation electrode.


In some embodiments, lead 100 can be configured to allow both a stylet or catheter delivery. For example, an opening can be left through the middle of the lead to allow a stylet to be used.



FIG. 2 shows a distal portion of lead 100. In this cross-section view of interatrial septum 30, it is seen that septum 30 includes a first side 32 facing right atrium 14 and a second side 34 facing left atrium 28. In a normal adult, septum 30 is usually between about 3 mm to 5 mm thick.


In one embodiment, retaining member 150 includes an expandable member 250. Expandable member 250 can include a balloon or other structure that has a first orientation where the balloon is relatively flush with the lead body outer surface and is expandable in vivo after a distal end 113 of the lead has past through second side 34 of the interatrial septum. In one embodiment, expandable member 250 can be made of biocompatible material. In some embodiments, expandable member 250 can include a self-expanding structure made from a shape memory material, such as NiTi, for example.


The lead is designed such that after the lead is inserted through septum 30, expandable member 250 is expanded. Expandable member 250 has an outer, cross-section dimension (D) that is larger than the outer diameter (dd) of the distal portion 109 of the lead. Thus member 250 abuts the surface on the left atrium side of the septum to retain the lead and electrode 122 as implanted. Electrode 122 is positioned relative to expandable member 250 such that the electrode is at or within septum 30. Therapy can then be delivered directly to the septum allowing for stimulation of the left atrium and right atrium simultaneously.


In one embodiment, lead 100 includes a second electrode 124 that can be used as a sensing or pacing electrode. Electrode 124 is located proximally from electrode 122 and is located at or near interatrial septum 30 when the lead is implanted. Electrode 124 can be used for sensing cardiac activity near the septum. This information is delivered to the pulse generator and the pulse generator can use the information to deliver therapy pulses to the heart.



FIG. 3 shows a distal portion of a lead 300 according to one embodiment. Lead 300 can include any features of lead 100, or any of the leads discussed below, and the discussions above and below are incorporated herein by reference. Lead 300 includes electrodes 122, 124 and a retaining member 150 including an umbrella structure 350. Umbrella structure 350 includes an expandable structure having a first orientation where one or more tines 356 of the umbrella structure are generally flush against the lead body. The tines 356 can be hinged to the distal end of lead 300 and can be opened by manipulating an actuating suture extending through the lead body to expand the tines into a second, expanded orientation where the outer diameter of the umbrella structure 350 has a greater diameter than the diameter of the distal end of the lead. Again, this holds the lead in position at the interatrial septum. In some examples, tines 356 can be shape memory material or biased members so as to be self-expanding.


In one embodiment, lead 300 (or lead 100 discussed above), can include a drug elution member 352, which can elute steroids, for example, to reduce inflammatory response of the tissue. Member 352 can be located on the distal end of the lead proximate member 150. In one embodiment, member 352 is located distally from electrode 150.


In this example, electrodes 122 and 124 are positioned such that pacing electrode 122 is within and contacting the septum 30 when retaining member 150 is opened on the left atrium side of septum 30, and electrode 124 is at or near the septum.



FIG. 4 shows a distal portion of a lead 400 according to one embodiment. Lead 400 can include any features of the leads discussed above or below and the discussions are incorporated herein by reference. Lead 400 includes electrodes 122, 124, and a retaining member 150 that includes a pre-biased section 450. For example, pre-biased section 450 can include a pre-formed L-hook or J-hook shape 452 at a distal end 409 of the lead. Pre-biased section 450 is located distally from electrode 122 so that electrode 122 is at or within septum 30 when section 450 is deployed within left atrium 28.


To pre-form section 450 of lead 400, the lead can be manufactured such that it is biased with the shape 452. Thus, the lead naturally reverts to the pre-biased shape when it is implanted. For example, the lead body can be formed in the pre-biased shape or the conductor coils can be formed in the pre-biased shape to bias the lead body into the shape. A stylet or catheter can be used to implant the lead until the distal tip is across septum 30 and within left atrium 28. Then the stylet or catheter is removed and the pre-formed shape 452 returns to its pre-biased shape helping retain the lead in its implanted position, since in its expanded or biased orientation the shape defines an overall outer dimension greater than the dimension of the diameter of the distal end of the lead and thus greater than the hole through the septum.



FIG. 5 shows a distal portion of a lead 500 according to one embodiment. Lead 500 can include any of the features discussed above or below for other leads described herein. Lead 500 includes electrodes 122 and 124, and a retaining member 150 such as an expandable member 550. In one embodiment, lead 500 includes a sensor 555, which can be a flow sensor or pressure sensor. Sensor 555 can be connected to pulse generator 110 (FIG. 1) through a conductor. In one example, sensor 555 can be a blood flow sensor, such as a metal ring or coil. Such a component has resistance properties such that if a pulse of energy were sent through the component, the component would heat up. This in turn would increase the component's electrical resistance. The electrical resistance could be monitored over time to determine how the resistance changes as the blood flow past it cools it down to blood temperature.


In other embodiments, sensor 555 can be a pressure sensor. In other embodiments, sensor 555 can be a CO2 sensor or an O2 sensor. Sensor 555 can be used to provide pacing ands sensing information to the pulse generator to deliver pulses or modify the settings of the pulse generator.


Lead 500 can also include a radio-opaque marker 560 near the distal tip to help a physician guide the lead when viewed under fluoroscopy.


In use, any of leads described herein can be implanted by inserting the lead through the superior vena cava into the right atrium and then through the interatrial septum. The distal retaining mechanism is deployed once the tip of the lead is into the left atrium. For example, a transeptal sheath catheter with dilator and needle on the tip can be used to perforate the interatrial septum. The catheter is advanced into the left atrium and the dilator is removed. The lead is inserted into the catheter and the distal end is expanded using one of the techniques, as discussed above. The electrode placement can be tested for therapeutic parameters, and the catheter is removed. The electrode 122 is then located at or within the septum and electrode 124 is just proximal from electrode 122. This allows for pacing and sensing of the left atrium, right atrium, or synchronized pacing of the left and right atria. The implantation technique is simpler and easier to do than other techniques to deliver energy pulses to the left atrium. Moreover, the present lead allows for synchronized pacing utilizing a single electrode and the position of the electrode is optimized at the interatrial septum due to the retaining member of the leads.


In some embodiments, the leads discussed herein provide benefits when used for left atrial pacing and sensing. For example, for DDD pacing, the atrial-ventricular (AV) delay interval of the present system can be adjusted to an optimal setting. Also, pacing the left atrium and the right atrium simultaneously can suppress reentrant atrial arrhythmia. Moreover, synchronous depolarization of both the right atrium and left atrium can decrease atrial extrasystoles and interfere with reentrant circuits. The lead allows for optimization of left side timing intervals and can result in an atrial anti-arrhythmic pacing therapy when integrated with certain algorithms, such as, for example, pacing on premature atrial beats.


The present design allows for very little lead presence in the left atrium, thus not requiring special non-thrombogenic material on the lead, although some embodiments can include such material. For example, in one embodiment, at least a portion of one of the leads discussed herein can include an anti-thrombosis coating, such as HYPREN or polyethleneglycol for example. The coating can be placed on the lead body, for example, or on an electrode, on an expandable member, or on other segments of the lead.



FIG. 6 shows a distal portion of a lead 600 in accordance with one embodiment. Lead 600 can include features of other leads discussed herein. Lead 600 includes electrodes 122, 124, and a retaining member 150, such as expandable member 650, which can be a balloon or other retaining member as discussed above. In one embodiment, lead 600 includes a second retaining member 655 located proximally from retaining member 650. Second retaining member 655 can be an expandable member, such as a balloon, or other retaining member as discussed herein. Second retaining member 655 is located on lead 600 so as to be located on side 32 of interatrial septum 30 when retaining member 650 is on side 34. Thus, the two retaining members sandwich septum 30 between each other. This can help further stabilize electrodes 122, 124.



FIG. 7 shows a view of a lead 700, according to one embodiment, implanted within heart 10. Lead 700 can include any features as discussed above or below for other leads. Lead 700 is adapted to deliver AF/AT shock treatment via a defibrillation shock electrode 730, which is positioned against the interatrial septum 30. A pacing/sensing electrode 722 can be located on a distal section of the lead and contact the septum. A retaining member 750 is located on a distal end 709 of the lead and adapted to be located within left atrium 28 to hold electrode 730 in position against the septum. This allows the lead to deliver electrical shocks via electrode 730 to the left atrium without requiring the electrode itself to be fixated within the left atrium.


In one embodiment, electrode 730 includes a defibrillation coil electrode adapted for delivering shock pulses to heart 10. Lead 700 can be designed for placement of shock electrode 730 against the septum 30 to deliver shock pulses to the left atrium 28. Electrode 730 can include a shocking coil electrode designed to deliver energy pulses of approximately 0.1 to 50 Joules. By providing direct shocking of the left atrium, the present system can delivery therapy using less energy than if the electrode were located within the coronary sinus, for example.


In one embodiment, lead 700 includes a second shocking electrode 752 which is located on an intermediate portion 702 of the lead so as to be located in the superior vena cava 12 or right atrium 14 when first electrode 730 is against the interatrial septum. In one embodiment, electrode 752 includes a shock electrode adapted for delivering shock pulses to heart 10. Electrode 730 can include a coil electrode designed to deliver energy pulses of approximately 0.1 to 50 Joules. The second shocking electrode 752 minimizes the left atrial shocking energy required so as to help minimize any discomfort of the patient.


In one embodiment, pacing/sensing electrode 722 can include a ring electrode positioned so as to be located near or within interatrial septum 30. Electrode 722 can be used for sensing atrial activity as well as delivering pacing pulses to the left atrium, the right atrium, or synchronized pacing to both atria, such as discussed above.



FIGS. 8 and 9 show further details of lead 700. FIG. 8 shows lead 700 implanted at interatrial septum 30 and FIG. 9 shows a side view of the lead in its unimplanted state. As discussed, lead 700 includes a retaining member 750, such as an expandable balloon 753, on a distal end 709 of the lead body and located distally from electrode 730. In some embodiments, retaining member 750 can include any of the retaining members discussed above, such as an expandable umbrella structure or a pre-formed L-shape or J-shape distal portion section. Retaining member 750 includes an expanded orientation having a larger outer diameter than a diameter of the distal end of the lead body. Accordingly, retaining member 750 holds the lead in place such that shocking electrode 730 abuts against the surface of interatrial septum 30 on the left atrial side 32 of the septum.


In one embodiment, lead 700 includes a less stiff, or more flexible, section 804, which is less stiff than adjacent sections of the lead. Less stiff section 804 is located proximally from electrode 730. This enables electrode 730 to fall naturally against the interatrial septum wall when the lead is implanted since the less stiff section does not provide a biasing counterforce when the electrode is positioned flush against the septal wall. This enhances the electrode stability and contact. Moreover, less stiff section 804 reduces and dampens forces transferred to the site of electrode contact due to motion of the heart against other portions of the lead body.


In one embodiment, less stiff section 804 includes a different, more pliable material than adjacent sections of the lead body. In some embodiments, less stiff section 804 includes a smaller diameter than adjacent sections of the lead body. In some embodiments, less stiff section 804 can be formed by providing a lead wall having a different inner diameter thickness, or by providing a less stiff conductor coil at that location.


In one embodiment, lead 700 includes a pre-biased curved section 802 between shocking electrode 730 and retaining member 750. In some embodiments, pre-biased curved section 802 defines an angle β in the lead body of about 30 degrees to about 120 degrees. In some embodiments, pre-biased curved section 804 defines an angle β in the lead body of about between 85 degrees to about 95 degrees. In some embodiments, pre-biased curved section 804 defines an angle β in the lead body of about 90 degrees. Pre-biased curved section 802 is shaped to force or bias the shocking electrode 730 towards the septum surface so as to abut against the side 32 surface of interatrial septum 30 such that the electrode lies lengthwise against the septal surface when the distal end of the lead extends through the septum in a generally perpendicular direction. This enhances the electrode surface area contact with the surface of the septum. Moreover, the curved section 802 and retaining member 750 act to sandwich the septum between themselves to help hold the lead in place.


As discussed, lead 700 can include a pacing or sensing electrode 722 on the distal end of the lead. In one embodiment, electrode 722 is located between shocking electrode 730 and retaining member 750 so as to be at or within septum 30 when the lead is implanted. Electrode 722 can be used for sensing of cardiac activity and/or for delivering pacing pulses to left atrium 28 or synchronized pacing to the left and right atria.


In some embodiments, lead 700 can include radio-opaque markers near the distal tip to help a physician guide the lead when viewed under fluoroscopy, such as discussed above. In some embodiments, lead 700 can include flow or pressure sensors on a distal end of the lead, such as discussed above for lead 500 (FIG. 5).


In an example use of lead 700, the lead is inserted through the superior vena cava and into the right atrium, using a stylet or catheter delivery. The distal tip of the lead is inserted through the interatrial septum and a retaining member is deployed on the left atrium side of the interatrial septum. The pre-biased curved section of the lead biases the electrode towards the septal surface while the less stiff section does not try to force it away from the surface. Thus the electrode can lie flush against the surface of the septal wall. The lead is coupled to a pulse generator and energy pulses are delivered to the heart. The lead can be used for direct left atrial shocking to treat AF/AT. The direct shock allows the system to decrease shock energy and increase conversion efficacy.


Again, the lead as described above allows for very little lead presence in the left atrium, thus not requiring special non-thrombogenic material on the lead, although some embodiments can include such material. For example, in one embodiment, at least a portion of one of the leads discussed herein can include an anti-thrombosis coating, such as HYPREN or polyethleneglycol for example. The coating can be placed on the lead body, for example, or on an electrode or on other segments of the lead.


It is understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. A method comprising: inserting a distal tip of a lead through an interatrial septum;deploying a retaining member on the lead on a left atrial side of the interatrial septum;providing a curved section on the lead so as to bias an electrode disposed on the lead towards a right atrial side surface of the interatrial septum; anddelivering energy pulses to the interatrial septum via the electrode.
  • 2. The method of claim 1, wherein delivering energy pulses includes delivering defibrillation pulses.
  • 3. The method of claim 1, wherein deploying a retaining member includes expanding a balloon on the left atrial side of the interatrial septum.
  • 4. The method of claim 1, wherein deploying a retaining member includes opening an umbrella structure on the left atrial side of the interatrial septum.
  • 5. The method of claim 1, wherein deploying a retaining member includes allowing a pre-biased section of the lead body to return to its pre-biased shape on the left atrial side of the interatrial septum.
  • 6. The method of claim 1, further including providing a less stiff section on the lead so that the electrode is between the less stiff section and the curved section.
  • 7. A method comprising: providing a lead including a lead body extending from a proximal end to a distal end and having an intermediate portion, the lead having a first electrode disposed proximate the distal end of the lead body, a retaining member disposed proximate the distal end of the lead, and a defibrillation shock electrode disposed along the lead proximal from the first electrode, wherein the lead body further includes a pre-biased curved section located between the retaining member and the defibrillation shock electrode;inserting the distal end of the lead through an interatrial septum; anddeploying the retaining member on the lead on a left atrial side of the interatrial septum such that the first electrode contacts the interatrial septum and the defibrillation shock electrode is biased toward the intratrial septum by the pre-biased curved section.
  • 8. The method of claim 7, wherein deploying a retaining member includes expanding a balloon on the left atrial side of the interatrial septum.
  • 9. The method of claim 7, wherein deploying a retaining member includes opening an umbrella structure on the left atrial side of the interatrial septum.
  • 10. The method of claim 7, wherein deploying a retaining member includes allowing a pre-biased section of the lead body to return to its pre-biased shape on the left atrial side of the interatrial septum.
  • 11. The method of claim 7, further including delivering energy pulses from at least one of the electrodes.
  • 12. The method of claim 11, wherein delivering energy pulses includes delivering pacing pulses.
  • 13. The method of claim 11, wherein delivering energy pulses includes delivering defibrillation pulses.
  • 14. A method comprising: providing a lead including a lead body extending from a proximal end to a distal end and having an intermediate portion, the lead body including a shocking electrode disposed proximate the intermediate portion of the lead body, and a retaining member disposed on the lead body and located distally from the shocking electrode, wherein the lead body includes a pre-biased curved section between the shocking electrode and the retaining member;inserting the distal end of the lead through an interatrial septum; anddeploying the retaining member on the lead on a left atrial side of the interatrial septum such that the defibrillation shock electrode is biased toward the intratrial septum by the pre-biased curved section.
  • 15. The method of claim 14, wherein deploying a retaining member includes expanding a balloon on the left atrial side of the interatrial septum.
  • 16. The method of claim 14, wherein deploying a retaining member includes opening an umbrella structure on the left atrial side of the interatrial septum.
  • 17. The method of claim 14, wherein deploying a retaining member includes allowing a pre-biased section of the lead body to return to its pre-biased shape on the left atrial side of the interatrial septum.
  • 18. The method of claim 14, wherein the lead body further includes a less stiff section located proximally from the shocking electrode.
  • 19. The method of claim 14, wherein the pre-biased curved section defines an angle in the lead body of about between 85 degrees to about 95 degrees.
RELATED APPLICATIONS

This application is a Divisional Application of U.S. application Ser. No. 10/920,695, filed on Aug. 18, 2004, now U.S. Pat. No. 7,515,970, which is incorporated herein by reference in its entirety.

US Referenced Citations (233)
Number Name Date Kind
1251258 Magill Dec 1917 A
1756670 Treat Apr 1930 A
1918890 Bacon Jul 1933 A
2434030 Yeomans Jan 1948 A
2453056 Zack Nov 1948 A
2707783 Sullivan May 1955 A
3040748 Klein eet al. Jun 1962 A
3080564 Strekopitov et al. Mar 1963 A
3193165 Akhalaya et al. Jul 1965 A
3217557 Martinot Nov 1965 A
3252643 Strekopytov et al. May 1966 A
3254650 Collito Jun 1966 A
3254651 Collito Jun 1966 A
3269630 Fleicher Aug 1966 A
3388847 Kasulin et al. Jun 1968 A
3452615 Gregory Jul 1969 A
3494533 Green et al. Feb 1970 A
3519187 Kapitanov Jul 1970 A
3552626 Astafiev et al. Jan 1971 A
3570497 Lemole Mar 1971 A
3589589 Akopov Jun 1971 A
3593903 Astafiev et al. Jul 1971 A
3638652 Kelley Feb 1972 A
3657744 Ersek Apr 1972 A
3692224 Astafiev et al. Sep 1972 A
3774615 Lim et al. Nov 1973 A
3805793 Wright Apr 1974 A
3908662 Razgulov et al. Sep 1975 A
4076162 Kapitanov et al. Feb 1978 A
4140126 Choudhury Feb 1979 A
4166466 Jarvik Sep 1979 A
4214587 Sakura, Jr. Jul 1980 A
4233981 Schomacher Nov 1980 A
4304236 Conta et al. Dec 1981 A
4319576 Rothfuss Mar 1982 A
4325376 Klieman et al. Apr 1982 A
4350160 Kolesov et al. Sep 1982 A
4351466 Noiles Sep 1982 A
4352358 Angelchik Oct 1982 A
4366819 Kaster Jan 1983 A
4368736 Kaster Jan 1983 A
4466436 Lee Aug 1984 A
4505414 Filipi Mar 1985 A
4523592 Daniel Jun 1985 A
4553542 Schenck et al. Nov 1985 A
4573468 Conta et al. Mar 1986 A
4576167 Noiles Mar 1986 A
4586503 Kirsch et al. May 1986 A
4592354 Rothfuss Jun 1986 A
4593693 Schenck Jun 1986 A
4603693 Conta et al. Aug 1986 A
4607637 Berggren et al. Aug 1986 A
4624255 Schenck et al. Nov 1986 A
4624257 Berggren et al. Nov 1986 A
4646745 Noiles Mar 1987 A
4657019 Walsh et al. Apr 1987 A
4665906 Jervis May 1987 A
4681110 Wiktor Jul 1987 A
4700703 Resnick et al. Oct 1987 A
4703887 Clanton et al. Nov 1987 A
4747407 Liu et al. May 1988 A
4800882 Gianturco Jan 1989 A
4836204 Landymore et al. Jun 1989 A
4872874 Taheri Oct 1989 A
4907591 Vasconcellos et al. Mar 1990 A
4917087 Walsh et al. Apr 1990 A
4917090 Berggren et al. Apr 1990 A
4917091 Berggren et al. Apr 1990 A
4940064 Desai Jul 1990 A
4957499 Lipatov et al. Sep 1990 A
5000185 Yock Mar 1991 A
5035702 Taheri Jul 1991 A
5064435 Porter Nov 1991 A
5102417 Palmaz Apr 1992 A
5104399 Lazarus Apr 1992 A
5119983 Green et al. Jun 1992 A
5141516 Detweiler Aug 1992 A
5177112 Horn Jan 1993 A
5188638 Tzakis Feb 1993 A
5190528 Fonger et al. Mar 1993 A
5197649 Bessler et al. Mar 1993 A
5234447 Kaster et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5242457 Akopov et al. Sep 1993 A
5250058 Miller et al. Oct 1993 A
5256661 Horn Oct 1993 A
5258042 Mehta Nov 1993 A
5269319 Schulte et al. Dec 1993 A
5271543 Grant et al. Dec 1993 A
5292053 Bilotti et al. Mar 1994 A
5304220 Maginot Apr 1994 A
5312341 Turi May 1994 A
5324447 Lam et al. Jun 1994 A
5330503 Yoon Jul 1994 A
5333773 Main et al. Aug 1994 A
5336233 Chen Aug 1994 A
5348259 Blanco et al. Sep 1994 A
5366462 Kaster et al. Nov 1994 A
5366473 Winston et al. Nov 1994 A
5387235 Chuter Feb 1995 A
5395030 Kuramoto et al. Mar 1995 A
5397345 Lazarus et al. Mar 1995 A
5397355 Marin et al. Mar 1995 A
5403333 Kaster et al. Apr 1995 A
5443477 Marin et al. Aug 1995 A
5452733 Sterman et al. Sep 1995 A
5456714 Owen Oct 1995 A
5478354 Tovey et al. Dec 1995 A
5489295 Piplani et al. Feb 1996 A
5522834 Fonger et al. Jun 1996 A
5549619 Peters et al. Aug 1996 A
5554162 DeLange Sep 1996 A
5562690 Green et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5571163 Helland Nov 1996 A
5620452 Yoon Apr 1997 A
5634936 Linden et al. Jun 1997 A
5669918 Balazs et al. Sep 1997 A
5676670 Kim Oct 1997 A
5695504 Gifford, III et al. Dec 1997 A
5707380 Hinchliffe et al. Jan 1998 A
5709335 Heck Jan 1998 A
5720755 Dakov Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5732872 Bolduc Mar 1998 A
5735290 Sterman et al. Apr 1998 A
5755775 Trerotola et al. May 1998 A
5755777 Chuter May 1998 A
5797933 Snow et al. Aug 1998 A
5800526 Anderson et al. Sep 1998 A
5817113 Gifford, III et al. Oct 1998 A
5830222 Makower Nov 1998 A
5833698 Hinchliffe et al. Nov 1998 A
5839639 Sauer et al. Nov 1998 A
5843164 Frantzen et al. Dec 1998 A
5843170 Ahn Dec 1998 A
5855210 Sterman et al. Jan 1999 A
5855592 McGee et al. Jan 1999 A
5868760 McGuckinns et al. Feb 1999 A
5868763 Spence et al. Feb 1999 A
5879380 Kalmann et al. Mar 1999 A
5881943 Heck et al. Mar 1999 A
5902330 Ollivier et al. May 1999 A
5904697 Gifford, III et al. May 1999 A
5906607 Taylor et al. May 1999 A
5927284 Borst et al. Jul 1999 A
5931842 Goldsteen et al. Aug 1999 A
5938660 Swartz et al. Aug 1999 A
5941908 Goldsteen et al. Aug 1999 A
5951576 Wakabayashi Sep 1999 A
5951597 Westlund et al. Sep 1999 A
5972017 Berg et al. Oct 1999 A
5976159 Bolduc et al. Nov 1999 A
5976176 Webb, II Nov 1999 A
5976178 Goldsteen et al. Nov 1999 A
6007544 Kim Dec 1999 A
6014590 Whayne et al. Jan 2000 A
6015378 Borst et al. Jan 2000 A
6019722 Spence et al. Feb 2000 A
6024748 Manzo et al. Feb 2000 A
6027476 Sterman et al. Feb 2000 A
6032672 Taylor Mar 2000 A
6035856 LaFontaine et al. Mar 2000 A
6036702 Bachinski et al. Mar 2000 A
6036705 Nash et al. Mar 2000 A
6051007 Hogendijk et al. Apr 2000 A
6063021 Hossain et al. May 2000 A
6066148 Rygaard May 2000 A
6071235 Furnish et al. Jun 2000 A
6071292 Makower et al. Jun 2000 A
6074416 Berg et al. Jun 2000 A
6080175 Hogendijk Jun 2000 A
6083234 Nicholas et al. Jul 2000 A
6095997 French et al. Aug 2000 A
6110187 Donlon Aug 2000 A
6110188 Narciso, Jr. Aug 2000 A
6113588 Duhaylongsod et al. Sep 2000 A
6113612 Swanson et al. Sep 2000 A
6120432 Sullivan et al. Sep 2000 A
6136007 Goldsteen et al. Oct 2000 A
6139492 Vierra et al. Oct 2000 A
6152937 Peterson et al. Nov 2000 A
6152945 Bachinski et al. Nov 2000 A
6165185 Shennib et al. Dec 2000 A
6165196 Stack et al. Dec 2000 A
6171321 Gifford, III et al. Jan 2001 B1
6176864 Chapman Jan 2001 B1
6183486 Snow et al. Feb 2001 B1
6186942 Sullivan et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6193734 Bolduc et al. Feb 2001 B1
6206912 Goldsteen et al. Mar 2001 B1
D440304 Morales Apr 2001 S
6240322 Peterfeso et al. May 2001 B1
6241741 Duhaylongsod et al. Jun 2001 B1
6245083 Black et al. Jun 2001 B1
6248112 Gambale et al. Jun 2001 B1
6254615 Bolduc Jul 2001 B1
6296630 Altman et al. Oct 2001 B1
6311693 Sterman et al. Nov 2001 B1
6328699 Eigler et al. Dec 2001 B1
6347247 Dev et al. Feb 2002 B1
6402767 Nash et al. Jun 2002 B1
6485496 Suyker et al. Nov 2002 B1
6506210 Kanner Jan 2003 B1
6510348 Clemens et al. Jan 2003 B2
6532378 Saksena et al. Mar 2003 B2
6565581 Spence et al. May 2003 B1
6574514 Partridge et al. Jun 2003 B2
6579311 Makower Jun 2003 B1
6584362 Scheiner et al. Jun 2003 B1
6602263 Swanson et al. Aug 2003 B1
6616675 Evard et al. Sep 2003 B1
6652567 Deaton Nov 2003 B1
6685726 Black et al. Feb 2004 B2
6702829 Bachinski et al. Mar 2004 B2
6966917 Suyker et al. Nov 2005 B1
7018387 Suyker et al. Mar 2006 B2
7022127 Suyker et al. Apr 2006 B2
7028692 Sterman et al. Apr 2006 B2
7153301 Swartz et al. Dec 2006 B2
7546166 Michels et al. Jun 2009 B2
7717854 Mann et al. May 2010 B2
7890188 Zhang et al. Feb 2011 B2
20020183769 Swanson et al. Dec 2002 A1
20030055441 Suyker et al. Mar 2003 A1
20040092972 Suyker et al. May 2004 A1
20040215307 Michels et al. Oct 2004 A1
20040230283 Prinzen et al. Nov 2004 A1
20050203551 Weadock et al. Sep 2005 A1
20050288693 Suyker et al. Dec 2005 A1
20060041300 Zhang et al. Feb 2006 A1
20060184221 Stewart et al. Aug 2006 A1
Foreign Referenced Citations (40)
Number Date Country
28 22 603 Nov 1979 DE
195 42 733 Jul 1997 DE
0 119 688 Sep 1984 EP
0 384 647 Aug 1990 EP
0 419 660 Apr 1991 EP
0 539 237 Apr 1993 EP
0 137 685 Jun 1998 EP
0 637 454 Nov 1999 EP
0 820 724 Mar 2000 EP
0 820 725 Mar 2000 EP
0 885 595 Aug 2001 EP
0 712 614 Apr 2003 EP
0 689 806 Aug 2003 EP
1518083 Mar 1968 FR
935490 Aug 1963 GB
2 038 692 Jul 1980 GB
2 108 418 May 1983 GB
7711347 Apr 1979 NL
995765 Feb 1983 SU
1097301 Jun 1984 SU
8908433 Sep 1989 WO
9517127 Jun 1995 WO
9610375 Apr 1996 WO
9614808 May 1996 WO
9802099 Jan 1998 WO
9819608 May 1998 WO
9819618 May 1998 WO
9819629 May 1998 WO
9819630 May 1998 WO
9819631 May 1998 WO
9819632 May 1998 WO
9819634 May 1998 WO
9819732 May 1998 WO
9847430 Oct 1998 WO
9855027 Dec 1998 WO
9921491 May 1999 WO
9938454 Aug 1999 WO
0027313 May 2000 WO
0053104 Sep 2000 WO
0074579 Dec 2000 WO
Non-Patent Literature Citations (28)
Entry
Spencer, William H., “Atrial Septal Pacing: Synchronising the Atria”, Cardiac Arrhythmias: Pacing & Electrophysiology: The Expert, Eurospace ;97, Chapter 51, (1998), 367-374.
Androsov, “New Method of Surgical Treatment of Blood Vessel Lesions,” Arch. Surg. 1956; 73:902-910.
Berrgen et al., “Clinical Experience with UNLINK 3M Precise Microvascular Anastomotic Device,” Scand J Plast Reconstr Hand Surg, 1993; 27: 35-39.
Calafiore, A.m. “Early Clinical Experience With a New Sutureless Anastomotic Device for Procimal Anastomosis of the Saphenous Vein to the Aorta,” The Journal of Thoracic and Cardiovascular Surgery, vol. 121, No. 5, pp. 854-858, May 2001.
Cooper et al., “Development of the Surgical Stapler with Emphasis on Vascular Anastomosis,” NY Acad..Sci. 1963;25:365-377.
Eckstein, f.s., et al., Sutureless Mechanical Anastomosis of a Saphenous Vein Graft to a Coronary Artery With a New Connector Device, The Lancet, pp. 931-932, vol. 357, Mar. 24, 2001.
Gentili et al., “A Technique for Rapid Non-suture Vascular Anastomosis,” Can J Neuro Sci, 1987;14(1):92-95.
Goetz et al., “Internal Mammary-coronary Artery Anastomosis: A Nonsuture Method Employing Tantalum Rings,” J Thorac Card Surg, 1961;41(3):378-386.
Gottlob et al., “Anastomoses of Small Arteries and Veins by Means of Bushings and Adhesive,” J Card Surg, 1968;9:337-341.
Guyton et al., “A Mechanical Device for Sutureless Aorta—Saphenous Vein Anastomosis,” Ann Thorac Surg, 1979;28:342-345.
Holt et al., “A New Technique for End-to-end Anastomosis of Small Arteries,” Surg Forum, 1960;11:242-243.
Inokuchi, “A New Type of Vessel-suturing Apparatus,” AMA Arch Surg, 1958;77:954-957.
Inokuchi, “Stapling Device for End-to-side Anastomosis of Blood Vessles,” Arch Surg, 1961;82:27-31.
Kirsch et al., “A New Method for Microvascular Anastomosis: Report of Experimental and Clinical Research,” American Surgeon, 1992;58:722-727.
Lanzetta et al., “Long-term Results of 1 Millimeter Arterial Anastomosis Using the 3M Precise Microvascular Anastomotic System,” Microsurgery, 1992;13:313-320.
Li et al., “End-to-side-anastomosis in the Dog Using the 3M Precise Microvascular Anastomotic System: A Comparative Study,” J Reconstruct Microsurg, 1991;7(4):345-350.
Miller, “The Russian Stapling Device,” Acad Sci, 1963;25:378-381.
Nakayama et al., “A Simple New Apparatus for Small Vessel Anastomosis (free autograft of the sigmoid included),” Surgery, 1962;52(6):918-931.
Narter et al., “An Experimental Method for Nonsuture Anastomosis of the Aorta,” Surg Gyne & Obs, 1964;362-364.
Nazari et al., “Expandable Prosthesis for Sutureless Anastomosis in Thoracic Aorta Prosthetic Substitution”,European Journal of Cardiothoracic Surgery, vol. 10, No. 11, 1996, pp. 1003-1009.
Olearchyk, “Vasilii I. Kolesov—A Pioneer of Coronary Revascularization by Internal Mammary-coronary Artery Grafting,” J Thorac Surg, 1988;96(1):13-18.
Ragnarsson et al., “Arterial End-to-side Anastomosis with the UNILINK System,” Ann Plastic Surg, 1989;22(3):405-415.
Ragnarsson et al, “Microvenous End-to-side Anastomosis: An experimental Study Comparing the UNILINK System and Sutures,” J Reconstruct Microsurg, 1989;5(3):217-224.
Rohman et al., Chapter IX—Cardiovascular Technique, “Double Coronary Artery-internal Mammary Artery Anastomoses, Tantalum Ring Technique,” Surg Forum, 1960;11:263-243.
J. Rosch et al., “Modified Gianturco Expandable Wire Stents in Experimental and Clincial Use”, Annals of Radiology, 1998, 31, 2, pp. 100-103.
Vogelfanger et al., “A Concept of Automation in Vascular Surgery: A Preliminary Report on a Mechanical Instrument for Arterial Anastomosis,” Can J Surg, 1958;58:262-265.
Werker etal., “Review of Eacilitated Approaches to Vascular Anastomosis Surgery”; The Society of Thoracic Surgeons, 1997; pp. S122-S127.
Scheltes et al., “Assessment of Patented Coronary End-to-Side Anastomotic Devices Using Michromechanical Bonding”, The Society of Thoracic Surgeons, 2000; pp. 218-221.
Related Publications (1)
Number Date Country
20090198297 A1 Aug 2009 US
Divisions (1)
Number Date Country
Parent 10920695 Aug 2004 US
Child 12384139 US